What Is Crinecerfont and How Does It Treat Classic CAH?
At a Glance
Crinecerfont (Crenessity) is an add-on medicine for people age 4 and older with classic CAH. It lowers signals that drive excess androgen production, which may let a doctor safely reduce steroid doses, but it does not replace daily steroids or emergency treatment.
In this answer
4 sections
Crinecerfont (sold under the brand name Crenessity) is a medication approved by the FDA in 2024 to treat classic congenital adrenal hyperplasia (CAH) in adults and children who are 4 years of age and older [1]. It works by reducing the brain signals that overstimulate the adrenal glands, which indirectly lowers excess androgen production [1]. By controlling these hormones through this alternate pathway, crinecerfont allows doctors to safely reduce a patient’s daily dose of steroid medications (like hydrocortisone) [2]. This helps lower the risk of long-term side effects associated with high steroid use, though it does not cure the condition or replace the need for baseline steroid treatments [3].
Who Can Take Crinecerfont?
Crinecerfont is approved as an add-on treatment for people with classic CAH due to 21-hydroxylase deficiency who are at least 4 years old [1]. It is taken as an oral medication, typically twice daily with meals [4]. It is designed to be used alongside your existing daily steroid replacement therapy, not as a replacement for it [3].
How Crinecerfont Works
In classic CAH, the body cannot make enough of the stress hormone cortisol [1]. Because cortisol levels are too low, the pituitary gland in the brain continuously sends signals—using a hormone called ACTH (adrenocorticotropic hormone)—telling the adrenal glands to work harder [1]. In someone with CAH, this constant stimulation does not produce cortisol, but instead causes the adrenal glands to produce excess androgens [1]. While often called “male hormones,” androgens are hormones made in everyone; in excess, they can cause severe acne, unwanted hair growth, early puberty in children, or fertility issues [2].
Historically, the standard way to quiet this brain signal and stop the excess androgen production was to give patients high doses of glucocorticoids (steroids like hydrocortisone or dexamethasone) [5]. These doses are often much higher than what the body naturally needs just to replace the missing cortisol [1].
Crinecerfont changes this approach. It is a CRF1 receptor antagonist [1]. It blocks the signaling pathway in the pituitary gland, which reduces the release of ACTH [1]. Because the adrenal glands receive less ACTH stimulation, androgen levels drop significantly without the need for extra high doses of steroids [6][4].
Reducing the Daily Steroid Dose
Because crinecerfont controls androgen levels by reducing ACTH, patients may no longer have to rely on supraphysiologic (higher than natural) doses of steroids for that purpose [2]. Clinical trials have shown that many patients taking crinecerfont can significantly reduce their daily steroid doses while keeping their hormone levels well-controlled [2][7].
- In a 24-week trial for adults, the average daily steroid dose was reduced by 27.3% [2].
- In a 28-week trial for children and adolescents, doses were reduced by an average of 18.0% [7].
Important: These numbers are averages from clinical trials, and individual results will vary. Your specific steroid dose reduction will be guided by your own androgen levels and symptoms, not a predetermined percentage [3][8].
Lowering the daily steroid dose is important because long-term exposure to high steroids can lead to serious health issues, such as stunted growth in children, osteoporosis, weight gain, and metabolic problems [8].
Important Safety and Considerations
Do not stop or change your steroid dose on your own.
While crinecerfont helps reduce the need for extra steroids, it does not cure adrenal insufficiency [3]. You will still need to take a daily physiologic dose of steroids—an individualized estimate of the baseline amount your body needs to function [3][8]. Patients with the salt-wasting form of CAH will also still need their mineralocorticoid (fludrocortisone) and salt supplements as prescribed [3].
Tapering and Adrenal Crisis Risk
When starting crinecerfont, the process of lowering your steroid dose must be done gradually and carefully supervised by your endocrinologist [3]. Dropping the steroid dose too quickly or too low can cause an adrenal crisis, a life-threatening emergency caused by dangerously low cortisol levels [9].
Adrenal Crisis Symptoms: Watch closely for severe weakness, repeated vomiting, an inability to keep medication down, severe abdominal pain, severe dizziness, or fainting [9][2].
If these occur, you must follow your sick-day rules, use your emergency hydrocortisone injection, and seek immediate medical care [3]. Crinecerfont is not an emergency medication and does not replace your emergency stress-dosing plan [3].
Side Effects and Interactions
In clinical trials, the most commonly reported adverse events varied by age [2][7].
Always take crinecerfont as directed, typically twice daily with meals [4]. Because other medications can interact with how crinecerfont works, make sure your care team reviews all your prescription drugs, over-the-counter medicines, and supplements [2].
Common questions in this guide
What is crinecerfont, or Crenessity, used for in classic CAH?
How does crinecerfont lower androgen levels?
Can I stop taking hydrocortisone after starting crinecerfont?
How is crinecerfont taken?
How will my steroid dose be reduced after starting crinecerfont?
What symptoms could signal an adrenal crisis while my steroid dose is lowered?
What side effects can crinecerfont cause?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Treatment options
Could crinecerfont be an add-on option for my classic CAH?
Steroid replacement
Would my steroid dose need adjusting, and who would guide any changes?
Side effects
What side effects should I watch for with this medicine?
Related questions
Show more
Get notified when new evidence is published on Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (9)
- 1
Crinecerfont: First Approval.
Lee A
Drugs 2025; (85(6)):839-843 doi:10.1007/s40265-025-02165-1.
PMID: 40240539 - 2
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
Auchus RJ, Hamidi O, Pivonello R, et al.
The New England journal of medicine 2024; (391(6)):504-514 doi:10.1056/NEJMoa2404656.
PMID: 38828955 - 3
Glucocorticoid reduction after starting crinecerfont in adult patients with classic CAH: practical perspectives.
Hamidi O, Auchus RJ, Correa R, et al.
The Journal of clinical endocrinology and metabolism 2026; (111(7)):1801-1812 doi:10.1210/clinem/dgag147.
PMID: 41921547 - 4
Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia.
Newfield RS, Sarafoglou K, Fechner PY, et al.
The Journal of clinical endocrinology and metabolism 2023; (108(11)):2871-2878 doi:10.1210/clinem/dgad270.
PMID: 37216921 - 5
The evolution of new approaches to the treatment of congenital adrenal hyperplasia.
Merke DP, Auchus RJ
Endocrine reviews 2026; doi:10.1210/endrev/bnag033.
PMID: 42639844 - 6
Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.
Auchus RJ, Sarafoglou K, Fechner PY, et al.
The Journal of clinical endocrinology and metabolism 2022; (107(3)):801-812 doi:10.1210/clinem/dgab749.
PMID: 34653252 - 7
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.
Sarafoglou K, Kim MS, Lodish M, et al.
The New England journal of medicine 2024; (391(6)):493-503 doi:10.1056/NEJMoa2404655.
PMID: 38828945 - 8
Glucocorticoid reduction after starting crinecerfont in pediatric patients with classic congenital adrenal hyperplasia: practical perspectives.
Nokoff NJ, Fechner PY, Kim MS, et al.
The Journal of clinical endocrinology and metabolism 2026; (111(8)):e1937-e1950 doi:10.1210/clinem/dgag192.
PMID: 42082437 - 9
Current and future perspectives on clinical management of classic 21-hydroxylase deficiency.
Yogi A, Kashimada K
Endocrine journal 2023; (70(10)):945-957 doi:10.1507/endocrj.EJ23-0075.
PMID: 37380491
This page is for informational purposes only and does not constitute medical advice. It explains crinecerfont use in classic CAH, but your endocrinology team must guide medication changes, steroid tapering, and emergency care.